Sandoz, CH1243598427

Sandoz stock trades at EUR 74.93 with CHF 30.2 billion value

Published on 10/09/2026 at 15:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Barclays kept Buy and a CHF 93.00 target for Sandoz stock on October 6, 2026. EUR 74.93 followed EUR 74.63 on October 9, 2026, plus 0.40 percent.

Key points in brief

  • Sandoz stock was EUR 74.93 at Lang & Schwarz on October 9, 2026, up 0.40 percent versus EUR 74.63.
  • The SIX-listed shares traded at CHF 69.72, within a CHF 47.73 to CHF 75.90 52-week range.
  • Market capitalization stood at CHF 30.2 billion and the price-to-earnings ratio was 56.2.
  • Barclays maintained a Buy rating and a CHF 93.00 target on October 6, 2026.
  • Sandoz is scheduled to report third-quarter sales on October 28, 2026.
Sandoz, CH1243598427, Illustration mit AI erstellt.
Sandoz, CH1243598427, Illustration mit AI erstellt.

Sandoz (CH1243598427) was trading at EUR 74.93 at Lang & Schwarz on October 9, 2026 at 3:29 p.m. CEST, while its market capitalization stood at CHF 30.2 billion. The euro quote was up 0.40 percent versus the Lang & Schwarz prior close of EUR 74.63.

Price holds near yearly high

The Lang & Schwarz bid was EUR 74.90 and the ask EUR 74.96 at the same timestamp. On the SIX Swiss Exchange, Sandoz was last at CHF 69.72 on October 9, 2026 at 3:15 p.m. CEST, with 284,486 shares traded against an average volume of 1,214,928.

The SIX price stood within the 52-week range of CHF 47.73 to CHF 75.90. At CHF 69.72, the stock was 8.14 percent below the 52-week high, calculated from the same-currency exchange quote.

Valuation and peer comparison

Sandoz carried a price-to-earnings ratio of 56.2 and a market capitalization of CHF 30.2 billion on October 9, 2026. The valuation places the company among large pharmaceutical businesses, while its generic and biosimilar portfolio remains the central operating profile.

Comparison with peers

Sandoz: plus 0.40 percent, P/E 56.2, market capitalization CHF 30.2 billion

Teva (NYSE, USD): plus 3.44 percent, P/E 65.4, market capitalization USD 47.3 billion

Viatris (NASDAQ, USD): minus 0.44 percent, P/E minus 48.4, market capitalization USD 20.2 billion

Analyst target and calendar

According to Business Insider on October 6, 2026, Barclays maintained a Buy rating and a CHF 93.00 price target for Sandoz. The report also cited quarterly revenue of CHF 5.63 billion and net profit of CHF 106.61 million for the quarter ended June 30, 2026.

Sandoz is scheduled to publish its third-quarter sales update on October 28, 2026, according to RTTNews. That date gives the market its next fixed company-specific reference point after the October 9 quotation.

Trading reference for investors

The Lang & Schwarz price of EUR 74.93 on October 9, 2026 was above the prior close of EUR 74.63, while the SIX quote was CHF 69.72 at 3:15 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Sandoz stock.

Sandoz stock facts

  • Company: Sandoz Group AG
  • ISIN: CH1243598427
  • Ticker: SDZ
  • Primary exchange: SIX Swiss Exchange
  • Price Lang & Schwarz (as of October 9, 2026, 3:29 p.m. CEST): EUR 74.93
  • Change versus prior close: plus 0.40 percent
  • Prior close Lang & Schwarz (October 8, 2026): EUR 74.63
  • Market capitalization: CHF 30.2 billion (as of October 9, 2026)
  • Sector / Industry: Healthcare / Drug Manufacturers - Specialty and Generic

Market context: Market report SMI.

More news and analyses on Sandoz stock

Disclaimer...

en | CH1243598427 | SANDOZ | boerse | 70279439 | bgmi